Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 4/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293323 | 0.79 | ASIC3 (0.62) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL12131981 | 0.77 | NNMT (0.43) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL13004722 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL828125 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL13538508 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL10283350 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL8385272 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL13154323 | 0.76 | NNMT (0.57) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL21573715 | 0.76 | NNMT (0.57) | NNMTGRM5ASIC3FEN1ALOX5AP | |
| SCHEMBL298258 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624024-B2 | EP2 antagonist compounds | RESERVOIR NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240182459-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-4359392-A1 | EP2 ANTAGONIST COMPOUNDS | Reservoir Neuroscience, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-2404922-B1 | QUINOXALINE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-8674096-B2 | Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| CN-102341399-A | Quinoxaline compounds | ASTELLAS PHARMA INC | 2012-02-01 | — | — | CN | disclosed |
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NNMT 817/4885GRM5 4037/4885ASIC3 4358/4885 |
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | NNMT 277/4885GRM5 3266/4885ASIC3 2431/4885 |
| US-12624024-B2 | EP2 antagonist compounds | PTGER1, PTGER2, PTGER4 | NNMT 3944/4885GRM5 1046/4885ASIC3 1189/4885 |
| US-20240182459-A1 | EP2 ANTAGONIST COMPOUNDS | PTGER2, PTGER1, PTGES2 | NNMT 3032/4885GRM5 369/4885ASIC3 1432/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | NNMT 271/4885GRM5 3821/4885ASIC3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.